Birelentinib is an investigational new drug that is being developed by for the treatment of immune thrombocytopenia (ITP), and chronic lymphocytic leukemia. It is a dual Bruton's tyrosine kinase (BTK) and tyrosine-protein kinase Lyn inhibitor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.